Open Access Critical Evidence Review

An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects - A review of the evidence

Seven days of prednisone reduced the body's response to insulin in healthy adults, primarily by decreasing peripheral glucose utilization. The study did not show a reduction in insulin binding in adipocytes. Independent research confirms acute insulin resistance, while receptor alterations require further specific evidence in human tissues, which remains insufficient.

Cite this article
Colonnese, A. (2026). An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects - A review of the evidence. Life Science Hub Journal. DOI: 10.5281/zenodo.24293898. https://lifesciencehub.info/en/an-in-vivo-and-in-vitro-study-of-the-mechanism-of-prednisone-induced-insulin-resistance-in-healthy
LIFE Science Hub - Journal of Science · 2026 / Nov

DOI 10.5281/zenodo.24293898

Article history
Dates
  • Published 16/11/2026
  • Updated 16/11/2026
Revisions
  1. v1.0 — 16/11/2026 Initial publication of the article.

LIFE Science Hub keeps a record of every published version of the article to ensure editorial transparency. Future revisions will appear here.

Stylized adipocyte in a laboratory with reduced glucose particles, illustrating acute insulin resistance induced by prednisone.
Adipocyte and glucose flow in a bright laboratory setting, illustrating how prednisone can reduce insulin sensitivity and glucose transport.

ABSTRACT

The original study evaluated whether seven days of prednisone could reduce insulin sensitivity in healthy individuals and which biological step was most involved. Ten normal-weight adults underwent hyperinsulinemic-euglycemic clamp tests, a technique that measures how much glucose the body can utilize while blood glucose levels are kept stable. A separate group of human fat cells was analyzed in the laboratory.

Prednisone increased fasting glycemia and insulin and reduced insulin-induced glucose utilization. In fat cells, no significant difference emerged in insulin binding to the receptor, while glucose transport decreased. Within the narrative framework of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the study contributes primarily to the description of acute glucocorticoid-induced insulin resistance, rather than the direct demonstration of lower insulin receptor or IRS-1 expression. Independent studies confirm the worsening of insulin sensitivity and indicate possible alterations of IRS-1 in muscle; however, other cellular data show that the defect may be localized primarily in glucose transport. The most prudent conclusion is therefore that the metabolic effect is well-documented, while the precise level of the insulin cascade depends on the tissue and the model studied.

Analyzed study

An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects

Pagano G, Cavallo-Perin P, Cassader M, Bruno A, Ozzello A, Masciola P, Dall'omo AM, Imbimbo B

The Journal of clinical investigation, 1983

DOI: 10.1172/jci111141

PMID: 6355186

PMCID: PMC370470

The research question was whether prednisone, a glucocorticoid used as an anti-inflammatory drug, induces a reduced response to insulin in healthy individuals through an insulin receptor defect or through a subsequent step inside the cell. The authors' hypothesis was that the drug could decrease the ability of insulin to promote the entry and utilization of glucose in tissues.

The relevance of the study stems from the fact that insulin does not act solely by lowering glycemia. After binding to its receptor, it initiates intracellular signals that primarily allow muscle and adipose tissue to utilize glucose. If these tissues respond less effectively, the pancreas tends to produce more insulin, and glycemia may increase.

In Chapter 4 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the publication is cited in three contexts: the initial insulin receptor signal, the role of IRS-1 and IRS-2 proteins, and the insulin resistance observable after brief exposure to prednisone. The most directly relevant finding is the latter: prednisone induced systemic insulin resistance in clinically healthy subjects. However, the study cannot demonstrate a reduction in receptor expression in muscle or liver, because the available material describes insulin binding only in isolated adipocytes and does not report measurements of receptor expression in muscle and liver tissues. It also cannot demonstrate a reduction in IRS-1 or its phosphorylation, as these variables are not reported in the available material.

Materials and methods of the original study

The available text is only the abstract; information not contained in the abstract is therefore not included in the available material. The human study involved 10 healthy, normal-weight subjects with a mean age of 35 ± 7 years. Each participant received prednisone, 15 mg twice daily, or a placebo—a treatment lacking the active ingredient—for seven days. The sequence was randomized, meaning it was assigned by chance, and the two phases were separated by approximately one month.

Before and during a hyperinsulinemic-euglycemic clamp, tritium-labeled glucose was infused, a substance that allows for tracking glucose fluxes within the body. The clamp was repeated at three stable insulin concentrations: approximately 100, 1,000, and 10,000 microU/ml. In simple terms, this method allows researchers to verify whether the body is able to utilize glucose when low, medium, or high levels of insulin are present.

The authors measured fasting glycemia and insulin, endogenous glucose production, and the insulin sensitivity index, expressed as the metabolic clearance rate of glucose. In a separate in vitro experiment—that is, outside the body—they analyzed adipocytes obtained from 16 normal-weight surgical candidates with a mean age of 40 ± 8 years. Ten had been treated with a placebo and six with prednisone according to the same regimen. Specific insulin binding and the cellular transport of 3-O-methyl-glucose, a molecule used to estimate glucose entry into the cell, were evaluated. Full inclusion and exclusion criteria, the sex of the participants, the randomization method, and further statistical details are not reported in the available material.

Results

Prednisone worsened the metabolic response to insulin. After treatment, fasting glycemia was higher compared to placebo, 89.5 ± 2.1 versus 83.7 ± 1.9 mg/dl, and fasting insulin was also higher, 17.8 ± 1.2 versus 14.3 ± 0.8 microU/ml; for both differences, the P-value was less than 0.01. In other words, even in healthy subjects, after one week of prednisone, more insulin was required in the presence of higher glycemia.

The most marked reduction concerned peripheral glucose utilization. The insulin sensitivity index, i.e., the amount of glucose removed from the blood in relation to body weight and time, was lower after prednisone at all insulin concentrations studied. At approximately 100 microU/ml, it was 2.8 ± 0.3 versus 7.4 ± 1.1 ml/kg/min; at approximately 1,000 microU/ml, it was 6.0 ± 0.5 versus 12.2 ± 1.1 ml/kg/min; at approximately 10,000 microU/ml, it was 7.4 ± 0.6 versus 14.4 ± 0.5 ml/kg/min. All these differences had a P-value of less than 0.001, and were therefore unlikely to be due to random variation.

Fasting glucose production by the body, largely attributable to the liver, was higher after prednisone: 3.7 ± 0.2 versus 2.9 ± 0.2 mg/kg/min, with a P-value of less than 0.001. However, according to the authors' interpretation, the observed insulin resistance was primarily due to reduced peripheral glucose utilization. During the clamp with approximately 100 microU/ml of insulin, the suppression of glucose production was less pronounced after prednisone, but the difference was not statistically significant. At higher insulin concentrations, suppression was complete both after prednisone and after placebo.

In adipose cells, specific insulin binding was not significantly different between prednisone and placebo. This is an important finding for interpreting sections 4.1 and 4.2 of the book: in the cellular model analyzed, the drug did not demonstrate a reduction in insulin binding to the receptor. Glucose transport, however, decreased after prednisone both under basal conditions, 0.40 ± 0.10 versus 0.54 ± 0.12 pmol per 100,000 cells, and at maximum insulin stimulation, 0.59 ± 0.04 versus 0.92 ± 0.12 pmol per 100,000 cells. The differences were associated with P-values of less than 0.05 and less than 0.005, respectively.

Interpretation

The main biological message is that prednisone can make tissues less capable of using glucose, even in people without diabetes. In the model studied, the problem did not appear primarily as an inability of insulin to bind to the fat cell. Instead, a subsequent defect emerged: after the initial signal, glucose was transported into the cell less effectively.

This distinguishes two levels of the insulin cascade. The first is the insulin receptor, the membrane protein that recognizes the hormone. The second includes post-receptor steps, i.e., the intracellular mechanisms that transform that signal into glucose uptake. The study analyzed places the defect primarily at the second level, because insulin binding to adipocytes did not change significantly, while glucose transport decreased.

The publication is therefore consistent with the passage in paragraph 4.14 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, which describes systemic insulin resistance after short exposures to prednisone. The correspondence with the sentences in paragraphs 4.1 and 4.2 is more limited. The work does not measure insulin receptor expression in muscle and liver and does not analyze IRS-1. The statement that prednisone would directly reduce the expression of the receptor or IRS-1 is therefore not documented by this specific study.

The main limitation is the small sample size: 10 subjects for the clinical part and 16 for the experiment on adipocytes. Furthermore, the duration was only seven days, and the participants were healthy and of normal weight. The results show an acute effect of the drug in this context, but they do not automatically define what happens after longer therapies, in elderly people, or in those with obesity, diabetes, or inflammatory diseases.

Independent confirmatory evidence

The most direct confirmation of the claim that short-term exposure to prednisone can induce insulin resistance in healthy subjects comes from a randomized study conducted on lean, healthy men. After one week, 25 mg of prednisone per day reduced whole-body glucose utilization by 35% during the first phase of the clamp and by 33% during the second phase compared to the placebo. Even 10 mg per day reduced glucose utilization by 15% in the second phase. The study therefore confirms the direction of the effect observed in the analyzed publication and shows a dose-response relationship. The limitation is that the sample included only healthy men and that the work was not designed to establish which intracellular protein produced the defect [1].

Regarding the section of the book concerning IRS-1, an experimental study examined human myotubes, rodent myotubes, muscle fragments, and mouse models. Dexamethasone, another glucocorticoid, reduced insulin-stimulated glucose uptake and decreased both the messenger RNA and the amount of IRS-1 protein. It also increased the phosphorylation of IRS-1 at serine 307, a modification associated with reduced insulin signaling efficacy. In mice, inhibition of the 11β-HSD1 enzyme reduced this inactivating modification of IRS-1 and improved insulin sensitivity. This research provides mechanistic support for the idea that excess glucocorticoid activity may involve IRS-1 in muscle, but it does not prove that prednisone produced the same effect in the participants of the original study [2].

Overall, independent evidence outlines a plausible sequence: pharmacological glucocorticoid → reduced tissue insulin response → reduced glucose utilization. The involvement of IRS-1 is supported primarily by cellular and animal models, while direct demonstration in humans for prednisone and for each specific tissue remains more limited.

Conflicting evidence

An experiment on 3T3-L1 adipocytes, murine cells commonly used to study adipose tissue, has highlighted a scenario that calls for caution in assuming the defect always lies at the same point in the insulin signaling cascade. After dexamethasone treatment, the expression of GLUT1, a basal glucose transporter, decreased by 30%; furthermore, the overall amount of GLUT4 did not change, but its translocation to the membrane in response to insulin was reduced. GLUT4 is the transporter that allows glucose to enter the cell when the insulin signal is received.

In the same model, insulin receptor phosphorylation was not altered by dexamethasone. The authors therefore attributed the insulin resistance primarily to a defect in glucose transport and GLUT4 translocation, rather than an initial blockage of the receptor signal [3]. This result is consistent with the original study regarding the reduction in glucose transport, but it limits the interpretation that glucocorticoids must necessarily reduce the insulin receptor or impair its binding.

This discrepancy does not deny that different glucocorticoids may influence IRS-1 or other intracellular signals in certain tissues. However, it shows that the mechanism may depend on the type of glucocorticoid, the dose, the duration of exposure, and the biological model. 3T3-L1 cells are not human adipose tissue in vivo; therefore, this evidence defines an interpretative limit, not a definitive clinical conclusion.

Summary table of evidence

The table distinguishes the results observed in the original study from the independent publications used to confirm or contextualize the specific narrative passage of the book.

Reference Study type Population or model Main result Direction of evidence Strength of evidence
Original study Randomized crossover study in humans and in vitro cell study 10 healthy normal-weight adults; adipocytes from 16 surgical candidates Seven days of prednisone reduced peripheral glucose utilization; insulin binding in adipocytes did not change significantly, while glucose transport decreased. direct confirmation moderate
[1] RCT with euglycemic-hyperinsulinemic clamp Healthy, lean men; sample size not reported in the available abstract One week of prednisone reduced whole-body glucose utilization in a dose-dependent manner compared to placebo. direct confirmation moderate
[2] Cellular, explant, and animal study Human and murine myotubes, muscle explants, and mice Dexamethasone reduced insulin-stimulated glucose uptake, reduced IRS-1, and increased an inactivating phosphorylation of IRS-1. biologically consistent evidence preliminary
[3] Cellular study Murine 3T3-L1 adipocytes Dexamethasone reduced glucose transport and GLUT4 translocation without altering insulin receptor phosphorylation. discordant evidence preliminary

Confirmation of the evidence

Claim in the book

In "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi, paragraphs 4.1 and 4.2 associate prednisone with an alteration of the insulin receptor and IRS-1; paragraph 4.14 further states that short exposures to prednisone can produce an increase in postprandial glycemia and systemic insulin resistance even in clinically healthy subjects.

Prednisone or other glucocorticoid → reduced tissue response to insulin → reduced glucose uptake and utilization → systemic insulin resistance

The publication subject to the Evidence Review was used in the book to support the following passage: short exposure to prednisone can induce insulin resistance in healthy subjects, primarily by reducing peripheral glucose utilization. The work also shows that, in the adipocytes studied, glucose transport decreases without a significant reduction in insulin binding.

The strongest correspondence relates to paragraph 4.14 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi. The original study observed that seven days of prednisone reduced insulin sensitivity in the body and glucose transport in adipocytes. An independent RCT confirmed that one week of prednisone reduces the body's glucose utilization during a clamp, with a greater effect at a dose of 25 mg compared to 10 mg [1].

The narrative regarding intracellular pathways can be completed, but not attributed entirely to the original publication. In human, rodent, and mouse muscle models, dexamethasone reduced IRS-1 and insulin-stimulated glucose uptake, providing mechanistic confirmation of the possibility that glucocorticoids alter signaling downstream of the receptor [2]. However, another adipocyte model showed that the defect may primarily involve GLUT4 translocation and glucose transport, without a detectable change in insulin receptor phosphorylation [3].

Consequently, independent literature well confirms the general direction of the narrative: pharmacological glucocorticoids can reduce insulin sensitivity and glucose utilization. It confirms the potential involvement of IRS-1 only at a mechanistic and model-dependent level. It does not directly confirm, through the original study, the specific claim of lower insulin receptor expression in muscle and liver.

Overall level of confirmation

MODERATE CONFIRMATION

Acute insulin resistance induced by prednisone is documented in the original study and confirmed by an independent RCT in humans. The involvement of IRS-1 is biologically plausible and supported by experimental studies, but the reduction of the insulin receptor in muscle and liver was not demonstrated by the publication under review and requires specific direct evidence.

Conclusions

The analyzed study shows that seven days of prednisone can reduce insulin sensitivity in healthy adults, primarily by decreasing peripheral glucose utilization. This finding is well-supported by independent clinical research using the euglycemic-hyperinsulinemic clamp technique.

However, the publication does not demonstrate a reduction in insulin receptor expression in the muscle or liver, nor a reduction in IRS-1 in the studied participants. Its cellular data points in a different direction: insulin binding to adipocytes was not significantly reduced, while glucose transport decreased. The involvement of IRS-1 remains mechanistically supported by other models, but requires direct validation in humans for the specific prednisone dosage, duration, and tissue.

Overall assessment

The narrative regarding insulin resistance induced by short-term exposure to prednisone is moderately supported by consistent, independent clinical data. The post-receptor mechanism, involving reduced glucose transport, is fairly well supported. However, specific claims regarding insulin receptor expression and IRS-1 require a more cautious and tissue-specific formulation.

References

[1] Short‐term metabolic effects of prednisone administration in healthy subjects

Kauh EA, Mixson LA, Shankar S, McCarthy J, Maridakis V, Morrow L, et al., 2011

Diabetes, Obesity and Metabolism

[2] 11b-Hydroxysteroid Dehydrogenase Type 1 Regulates Glucocorticoid-Induced Insulin Resistance in Skeletal Muscle

Morgan SA, Sherlock M, Gathercole LL, Lavery GG, Lenaghan C, Bujalska IJ, et al., 2009

Diabetes

[3] Dexamethasone-induced insulin resistance in 3T3-L1 adipocytes is due to inhibition of glucose transport rather than insulin signal transduction.

Sakoda H, Ogihara T, Anai M, Funaki M, Inukai K, Katagiri H, et al., 2000

Diabetes

Editorial note

Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.

The manuscript was also subject to independent peer review prior to publication.

To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.